01st week of 2013 patent applcation highlights part 46 |
Patent application number | Title | Published |
20130004507 | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES - Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 2013-01-03 |
20130004508 | ENGINEERED ANTI-TSLP ANTIBODY - The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders. | 2013-01-03 |
20130004509 | BRAF Mutations Conferring Resistance to BRAF Inhibitors - The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided. | 2013-01-03 |
20130004510 | VACCINE - Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein. | 2013-01-03 |
20130004511 | COMPOSITION COMPRISING INHIBITORS OF IRS-1 AND OF VEGF - Compositions comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway, which compositions rare useful for treating an angiogenic disease. The specification also relates to kits comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway, as well as methods of treating angiogenic diseases using such compositions and/or kits. | 2013-01-03 |
20130004512 | NUCLEIC ACID MOLECULES ENCODING BANK1 SPLICE VARIANTS - The present invention relates to a new splice variant of BANK1, the use of SNPs in BANK1 for diagnostics and the use of antagonists to modulate BANK1 and/or the BANK1 pathway. | 2013-01-03 |
20130004513 | AGENTS FOR TREATING DISEASE - Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof. | 2013-01-03 |
20130004514 | THERAPEUTIC ANTIBODIES - The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders. | 2013-01-03 |
20130004515 | METHODS FOR TREATING REPERFUSION INJURIES - The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin | 2013-01-03 |
20130004516 | DRUG FOR INFLAMMATORY BOWEL DISEASE - Anti-CD81 antibody displays not only a remission induction effect, but also a long-term remission maintenance effect on inflammatory bowel disease when administered in a single dose, and is therefore effective as a drug for maintaining remission from inflammatory bowel disease. Moreover, anti-CD81 antibody is effective as a drug for the prevention, amelioration and treatment of inflammatory bowel disease because it has preventive, therapeutic and ameliorating effects on refractory inflammatory bowel disease. | 2013-01-03 |
20130004517 | DISC-1 PATHWAY ACTIVATORS IN THE CONTROL OF NEUROGENESIS - The invention relates to methods of treating neurological disorders in a subject, by activating a DISC | 2013-01-03 |
20130004518 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT - Disclosed are compounds of the formula | 2013-01-03 |
20130004519 | SMOCI, TENASCIN-C AND BRAIN CANCERS - The present invention relates to a method for treating brain cancer in a subject by administering to said subject a therapeutically effective amount of a modulator of the interaction between SPARC related modular calcium binding 1 (SMOC1) and tenascin-C, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of SMOC1, as well as method of targeted therapy using anti-SMOC1 or tenascin-C antibodies conjugated to therapeutic agents. | 2013-01-03 |
20130004520 | METHODS AND MATERIALS RELATED TO HAIR PIGMENTATION AND CANCER - This document relates to methods and materials for determining whether or not a horse contains a Grey allele. For example, diagnostic methods such as nucleic acid-based detection methods and materials such as nucleic acid probes and primer pairs that can be used to determine whether or not a horse contains a duplication in intron 6 of STX17 nucleic acid are provided. This document also relates to methods and materials for treating a mammal having or being likely to develop cancer (e.g., benign, malignant, or metastatic cancer). For example, methods and materials for treating cancer in a mammal by administering an agent having the ability to reduce expression of an STX17 polypeptide and/or an NR4A polypeptide (e.g., an NR4A1, NR4A2, or NR4A3 polypeptide) in the mammal are provided. | 2013-01-03 |
20130004521 | TARGETING CANCER STEM CELLS - Provided is a method of determining the level of resistance or sensitivity of cancer stem cells to a death receptor agonist. The method includes detecting the level of IAP in one or more DR5/DDX3/IAP complexes in or from the cancer stem cells. Also provided is a method of killing cancer stem cells in a subject and a method of reducing the risk of cancer recurrence in a subject. | 2013-01-03 |
20130004522 | PHOTOTRIGGERED NANOPARTICLES FOR CELL AND TISSUE TARGETING - The present invention relates, in part, to a novel and simple particulate system that targets and binds any tissue selectively upon light illumination. The particulate system can be used for targeted delivery of substances to predefined cells or tissues in an individual. | 2013-01-03 |
20130004523 | THERAPEUTIC COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE AGENTS CLEAVABLY LINKED TO NANOPARTICLES - Various embodiments of the present invention pertain to therapeutic compositions that comprise: ( | 2013-01-03 |
20130004524 | Conjugated Proteins - The present invention relates to modified therapeutic proteins, such as e.g. coagula-tion factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group. | 2013-01-03 |
20130004525 | INACTIVATING PATHOGENS WITH OXIDIZING AGENTS FOR VACCINE PRODUCTION - The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided. | 2013-01-03 |
20130004526 | Utilization of Dialkylfumarates - The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also he used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines. | 2013-01-03 |
20130004527 | CONTIGUOUS OVERLAPPING PEPTIDES FOR TREATMENT OF RAGWEED POLLEN ALLERGY - Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of ragweed pollen Amb a 1. Such peptides while providing all potential T cell epitopes are devoid of the three-dimensional structure of the original allergen, therefore reducing their ability to bind IgE. | 2013-01-03 |
20130004528 | DIRECT ANALYSIS OF ANTIGEN-SPECIFIC IMMUNE RESPONSE - Provided herein are methods for the determination of antigen-specific CD4+ T cell phenotype and/or frequency, which is useful for detecting or monitoring immune function, directing immunotherapy to the use of those epitopes or antigen fragments that elicit an allergic reaction (e.g., as measured by detection of a Th2 response) and/or promote immune deviation, monitoring an immune response to a particular antigen, etc. | 2013-01-03 |
20130004529 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 2013-01-03 |
20130004530 | VACCINE COMPOSITION - Neisserial immunogenic compositions and vaccines, their manufacture and methods for the use of such compositions in medicine are provided herein. | 2013-01-03 |
20130004531 | IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI - Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic | 2013-01-03 |
20130004532 | PROCESS FOR MANUFACTURING VACCINES - The present application discloses an improved method for conducting saccharide—protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed. | 2013-01-03 |
20130004533 | PLATELET-DERIVED GROWTH FACTOR-BB PRODUCTION PROMOTOR, AND MESENCHYMAL STEM CELL PRODUCTION ACCELERATOR, STEM CELL STABILIZER AND DERMAL REGENERATOR COMPRISING THE SAME - An agent comprising one or more components selected from among cowberry derivatives, mangosteen derivatives, | 2013-01-03 |
20130004534 | INACTIVATION OF REVERSE TRANSCRIPTASES BY AZIDO-DIARYLPYRIMIDINES - Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided. | 2013-01-03 |
20130004535 | MULTIPLE VACCINATION INCLUDING SEROGROUP C MENINGOCOCCUS - Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular | 2013-01-03 |
20130004536 | MULTIPLE VACCINATION INCLUDING SEROGROUP C MENINGOCOCCUS - Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular | 2013-01-03 |
20130004537 | BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID - The present invention encompasses a recombinant bacterium comprising a regulated rfaH nucleic acid, as well as a vaccine comprising said recombinant bacterium. Other embodiments of the present invention encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and a regulated rfc nucleic acid, while additional embodiments encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and at least one nucleic acid encoding at least one exogenous antigen. | 2013-01-03 |
20130004538 | METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOGENIC OLIGONUCLEOTIDES - This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided. | 2013-01-03 |
20130004539 | METHODS FOR PREVENTING AND TREATING STAPHYLOCOCCUS AUREUS COLONIZATION, INFECTION, AND DISEASE - The invention provided herein relates to a method of preventing a | 2013-01-03 |
20130004540 | BIFIDOBACTERIUM STRAIN - strain AH121A is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent. | 2013-01-03 |
20130004541 | POLYMER NANOFIBER SCAFFOLD FOR A HEPARIN / FIBRIN BASED GROWTH FACTOR DELIVERY SYSTEM - A growth factor delivery scaffold combines a heparin/fibrin-based delivery system (HBDS) with a backbone based on polymer nanofibers for tissue (e.g., tendon and ligament) repair. The scaffold has improved surgical handling properties compared to the gelatinous consistency of the prior art HBDS system and retains the capability for delivering mesenchymal cells and controlling the release of growth factors. One application for the scaffold is mesenchymal stem cell (MSC) therapy for flexor tendon repair. The scaffold can deliver growth factors in a sustained manner, can be implanted for flexor tendon repair, is biocompatible, and is not cytotoxic. The growth factor delivery scaffold may also be used in the surgical repair of an injury to bone, muscle, cartilage, or other tissues. | 2013-01-03 |
20130004542 | COMPOSITION - The invention provides a composition for inhalation comprising a pharmaceutically acceptable glassy matrix and at least one bioactive material within the matrix, wherein the glassy matrix comprises a metal ion salt, wherein the composition is substantially free of polyols and is in the form of a powder and wherein the powder comprises particles having a median geometric diameter of less than 10 μm. | 2013-01-03 |
20130004543 | FIBRONECTIN: GROWTH FACTOR CHIMERAS - Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, or KGF and fibronectin, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of fibronectin. These protein complexes include synthetic proteins where the growth factor and fibronectin sequences are joined by a linker sequence. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer. | 2013-01-03 |
20130004544 | Synthetic Antibacterial Clay Compositions and Method of Using Same - The present invention is directed to synthetic bactericidal compositions having clay like properties and a method of using these compositions to topically treat bactenally-caused skin infections and skin diseases. The compositions within the scope of the invention compnse a bactericidal effective amount of a reducing agent, such as pyπte, marcasite, pyrrhotite, FeS2, FeS, FeS04—or other reducing agents having like properties, and a natural clay or clay mineral and/or synthetic clay or clay mineral, or other suitable matenals having clay-like properties. The synthetic bactericidal compositions are synthesized by adding the reducing agent to the clay or clay mineral. It is the presence of the reducing agent in said compositions that renders them bacteπcidal. The clays serve as a vehicle within which the reducing agent is dispersed, as a diluent to the reducing agent, and also as an adsorbent and low permeability banner in use of the composition | 2013-01-03 |
20130004545 | SLOW RELEASE PHARMACEUTICAL COMPOSITIONS OF ILOPERIDONE - A slow release pharmaceutical composition comprising iloperidone or its active metabolites and a slow release agent is described. Also disclosed is slow release pharmaceutical composition comprising iloperidone or its active metabolites, wherein the slow release composition is a combination of a controlled release composition and an immediate release composition. | 2013-01-03 |
20130004546 | HYDROGEL OF MICROSPHERES - The invention relates to an injectable composition intended for tissue induction of the soft tissues by a system of immediate and prolonged progressive release. | 2013-01-03 |
20130004547 | ORAL VACCINES PRODUCED AND ADMINISTERED USING EDIBLE MICRO-ORGANISMS INCLUDING LACTIC ACID BACTERIAL STRAINS - The invention provides for anti-pathogen vaccines produced in recombinant bacteria and/or transgenic plants and administered through standard vaccine introduction methods or oral administration. In one embodiment, the vaccine is administered through the consumption of the edible plant as food, or the bacteria administered orally. The present invention also provides a method of using genetically modified microorganisms, such as lactic acid bacteria, including | 2013-01-03 |
20130004548 | MEDICAL DEVICES HAVING PHARMACOLOGICAL ACTIVE AGENT RELEASING MATERIAL - An embodiment of the present invention relates to a therapeutically active composition for the treatment of arteriosclerosis, and a pharmacological active agent-releasing medical device, the efficiency of which is increased by combination with a compound that releases alkaline-earth metal ions. | 2013-01-03 |
20130004549 | CELL SUPPORT AND BONE REGENERATION MATERIAL - An object of the present invention is to provide a three-dimensional cell support that is capable of uniformly distributing cells and retaining the cells in a state without nonuniformity and is made of a biodegradable material. The present invention provides a cell support consisting of a porous body made of a biodegradable material, the porous body having the following properties:
| 2013-01-03 |
20130004550 | SUSTAINED-RELEASE SOLID PREPARATION FOR ORAL USE - It is intended to avoid dose dumping of a drug and improve the dissolution properties of the drug in the lower gastrointestinal tract, and thereby provide a sustained-release matrix preparation for oral administration that reliably exhibits its main pharmacological effect when orally administered once or twice a day. The present invention provides a sustained-release preparation obtained by mixing of (A) a pharmacologically active drug, (B) hydroxypropyl methylcellulose acetate succinate having a median size (D | 2013-01-03 |
20130004551 | BIOTINYLATED HEXADECASACCHARIDES, PREPARATION AND USE THEREOF - The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R | 2013-01-03 |
20130004552 | WATER DISPERSIBLE NONWOVEN FABRIC MATERIAL - Non-woven multi-layered fabric materials which include two external layers made of continuous filaments of a water-soluble or water dispersible polymer having an internal layer of a water-absorbent, flushable material are provided. Methods for making such non-woven multi-layered fabric materials, are also provided. | 2013-01-03 |
20130004553 | O/W Emulsion Composition - An O/W emulsion composition which is excellent in UV protection ability, formulation stability, and feeling in use. The O/W emulsion composition includes the following components (a) and (b): (a) organic UV absorbers comprising the following components (a1), (a2), and (a3): (a1) octocrylene, (a2) ethylhexyl methoxycinnamate, (a3) 4-t-butyl-4′-methoxydibenzoylmethane; and (b) a polyoxyethylene/polyoxyalkylene alkyl ether block polymer represented by the following formula (1) or (2); —R | 2013-01-03 |
20130004554 | Microalgae-Derived Compositions for Improving the Health and Appearance of Skin - Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin. | 2013-01-03 |
20130004555 | Cosmetic Compositions Comprising Esters Based on 2-Propylheptanol - The invention relates to the use of esters of 2-propylheptanol with benzoic acid and/or benzoic acid derivatives in cosmetic and/or pharmaceutical preparations. The compounds are distinguished by their particularly light sensory impression. | 2013-01-03 |
20130004556 | CHEWABLE FOAMS FOR COSMETIC PRODUCTS - The invention relates to novel chewable foams which are useful in the oral care sector and which are based on polyurethane-polyureas, to a method for the production of these novel chewable foams, and also to use thereof. | 2013-01-03 |
20130004557 | Antimicrobial Resin Compositions - Methods for making antimicrobial resins and for forming coatings comprising antimicrobial resins on substrate surfaces are disclosed. The methods involve providing a mixture comprising about 15 weight % to about 80 weight % of a hydrophilic acrylic oligomer, about 10 weight % to about 80 weight % of a multifunctional acrylic monomer, about 5 weight % to about 40 weight % of an adhesion-promoting acrylic or vinyl monomer, and about 0.1 weight % to about 15 weight % of a metal salt; and exposing the mixture to a radiation source to cure at least a portion of the mixture, thereby forming an antimicrobial resin. | 2013-01-03 |
20130004558 | POLYMER COMPOSITION AND MOLDED ARTICLES SHAPED OF THE SAME - The present invention relates to a molded article which is shaped of a polymer composition comprising 100 parts by weight of an olefin-based polymer, and 0.01 to 100 parts by weight of a C | 2013-01-03 |
20130004559 | FLAT SELF-CURLING PERMEABLE SHEET MEMBRANE - A flat self-curling permeable sheet membrane containing a matrix formed of crosslinked biopolymeric fibers. The matrix self-curls into a predetermined shape upon absorption of an aqueous fluid and is permeable to molecules having molecular weights not greater than 1×10 | 2013-01-03 |
20130004560 | Polymer Nanofilm Coatings - Disclosed herein are nanofilm coatings for implantable medical devices comprising a diblock or triblock copolymer (PEO-PMMA or PMOXA-PDMS-PMOXA, respectively). Such nanofilms, may be used, for example, as amphiphilic supports for therapeutic agents. These materials are conducive towards the formation of active substrates for a suite of biological and medical applications. | 2013-01-03 |
20130004561 | THERAPIES FOR PREVENTING OR SUPPRESSING CLOSTRIDIUM DIFFICILE INFECTION - The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of | 2013-01-03 |
20130004562 | PROCESS FOR PREPARING PURIFIED NUCLEIC ACID AND THE USE THEREOF - The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether) | 2013-01-03 |
20130004563 | MULTIPARTICULATE S-ADENOSYLMETHIONINE COMPOSITIONS AND RELATED METHODS - Multiparticulate compositions having S-adenosylmethionine an active ingredient are disclosed. The multiparticulates have spheroidal core comprising S-adenosylmethionine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions. | 2013-01-03 |
20130004564 | ANTIMICROBIAL PEPTIDES - The present invention relates to novel peptides having antimicrobial activity, and compositions containing the same. | 2013-01-03 |
20130004565 | PROTEOLYTIC ENZYME FORMULATIONS - Preferred embodiments of the present invention relate to proteolytic enzyme formulations. More specifically, several embodiments relate to a proteolytic formulation to facilitate digestion, metabolism, degradation of target compounds, and systemic enzymatic action. Embodiments for improving oxygenation and reducing plaque are also provided. | 2013-01-03 |
20130004566 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof | 2013-01-03 |
20130004567 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2013-01-03 |
20130004568 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2013-01-03 |
20130004569 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 2013-01-03 |
20130004570 | NUTRITIONAL SUPPLEMENT FOR USE UNDER PHYSIOLOGICALLY STRESSFUL CONDITIONS - In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 500 mg of vitamin C; about 400 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folic acid; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 75 mcg of biotin; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 10 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 400 mcg of lutein; about 125 mcg of lycopene; and at least one or more excipients. | 2013-01-03 |
20130004571 | Orally Effective Methylphenidate Extended Release Powder and Aqueous Suspension Product - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 2013-01-03 |
20130004572 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2013-01-03 |
20130004573 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE - The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile. | 2013-01-03 |
20130004574 | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointensinal tract - The preset invention provides a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a S-100 protein, b) an activated-potentiated form of an antibody to histamine, and c) an activated-potentiated form of an antibody to TNF-alpha. Various embodiments and variants are provided. | 2013-01-03 |
20130004575 | CONTROLLED RELEASE FORMULATIONS USING INTELLIGENT POLYMERS - A controlled release pharmaceutical composition comprises (a) topiramate or a pharmaceutically acceptable salt thereof, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component. The polymer components are effective for controlled release of the pharmaceutically active substance from the composition. | 2013-01-03 |
20130004576 | RIFAXIMIN POWDER, PROCESS FOR PREPARING THE SAME AND CONTROLLED RELEASE COMPOSITIONS CONTAINING SAID RIFAXIMIN USEFUL FOR OBTAINING A LONG-LASTING EFFECT - The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient. | 2013-01-03 |
20130004577 | COATED TABLET - A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (DMDO) group. The present invention provides a coated tablet characterized in that an uncoated tablet containing a drug having a guanidino group has been coated with a polyvinyl alcohol for film coating which comprises polyvinyl alcohol, acrylic acid, and methyl methacrylate. | 2013-01-03 |
20130004578 | Solid Pharmaceutical Dosage Formulation - The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor. | 2013-01-03 |
20130004579 | Use of Plant Lectins to Target Leukocytes - The present invention provides compositions and methods for targeting an antigen to leukocytes, delivering an antigen to leukocytes, increasing antigen uptake by leukocytes, and/or enhancing an immune response. In some embodiments, compositions and methods of the present invention comprise a conjugate comprising an antigen and a plant lectin or a mimetic thereof. | 2013-01-03 |
20130004580 | DIVALENT CATION/TALC CONTAINING COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING ENZYMATIC IRRITATION - Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a specified divalent cation, i.e., magnesium, in combination with talc. | 2013-01-03 |
20130004581 | CONTROLLING UPTAKE BY CELLS - Methods and devices for causing uptake of materials by cells, temporary using local chemical environment modification. The modification may be caused chemically by reducing pH. The uptake method is passive and does not require bioactivity of the cells. | 2013-01-03 |
20130004582 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form. | 2013-01-03 |
20130004583 | CELL HOMOGENATE FROM STEM CELLS DERIVED FROM GROWING DEER ANTLERS, A METHOD OF OBTAINING IT AND ITS USE - The subject of the present invention is a bioactive cell homogenate produced from cells belonging to the MIC-1 stem cell line derived from growing deer antlers (Cervidae) deposited at the DSMZ under the accession DSM ACC2854, a method of producing and using it. The present invention also encompasses a pharmaceutical or cosmetic composition containing the above-mentioned homogenate. | 2013-01-03 |
20130004584 | ANTI-INFLAMMATORY, RADIOPROTECTIVE, AND LONGEVITY ENHANCING CAPABILITIES OF CERIUMOXIDE NANOPARTICLES - The present invention provides cerium oxide nanoparticles for use both in therapeutic compositions in vivo and in research in vitro. The cerium oxide nanoparticles are of known range of sizes having biological properties that are reproducible and beneficial. Pharmaceutical and other compositions are provided, as are methods of treatment. | 2013-01-03 |
20130004585 | Method Of Manufacturing Antimicrobial Implants Of Polyetheretherketone - Methods of fabricating implantable medical devices, preferably with PEEK, having antimicrobial properties, are disclosed. The antimicrobial effect is produced by incorporating ceramic particles containing antimicrobial metal cations into molten PEEK resin, which is subsequently allowed to cool and set in its final shape achieved by injection molding, cutting and machining or other techniques. | 2013-01-03 |
20130004586 | Biologically Efficacious Compositions, Articles of Manufacture and Processes for Producing and/or Using Same - Compositions, solid polymeric compositions, and/or articles of manufacture are provided that can include a polymer matrix having a plurality of ion-exchange particles distributed therein. Products by process are provided that can include prior to solidifying the polymeric precursors, blending the precursors with ion-exchange particles to form a mixture, and solidifying the mixture to form a solid polymeric composition product. Solid polymeric composition production methods are also provided that can include providing a plurality of ion-exchange particles, prior to solidifying the polymeric precursors, blending the precursors with the ion-exchange particles to form a mixture, and solidifying the mixture to form a solid polymeric composition. Article of manufacture production methods are provided that can include incorporating a solid polymeric composition into an article of manufacture, the solid polymeric composition including a polymer matrix and a plurality of ion-exchange particles distributed therein. | 2013-01-03 |
20130004587 | Bioactive Acid Agrichemical Compositions and Use Thereof - Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations. | 2013-01-03 |
20130004588 | DIVALENT CATION CONTAINING COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING ENZYMATIC IRRITATION - Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation. | 2013-01-03 |
20130004589 | DIVALENT CATION/ANION PAIR CONTAINING COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING ENZYMATIC IRRITATION - Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation/anion pair. | 2013-01-03 |
20130004590 | ZINC OXIDE/ACID CONTAINING COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING ENZYMATIC IRRITATION - Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably zinc oxide in combination with an acid so as to release a specified divalent cation, i.e., zinc. | 2013-01-03 |
20130004591 | FORMULATION FOR RELIEF OF COLD AND FLU SYMPTOMS - A nutritional composition or functional food composition is provided comprising homeopathic ingredients for relieving the symptoms of colds and/or flus, in combination with traditional herbal and nutraceutical ingredients, and are efficacious as antipathogens. The formulation includes ingredients balanced in a synergistic manner to elicit complementary effects which both reduce the symptoms of colds and/or flus and provide the potential to reduce pathogenic loads in the body. Methods of making both the core medicinal formulation and suitable dietary supplement and/or functional food embodiments based on the formulation are provided. | 2013-01-03 |
20130004592 | PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION - The invention comprises various aqueous PEG-carbohydrate-lipid based formulations of pharmaceutical active ingredients including compositions for intravenous injections. This invention relates to methods and compositions for improving solubility and the safety profile of pharmaceutical compounds. More particularly, the present invention relates to employing PEG-carbohydrate-lipid conjugates for formulating drug compositions having increased solubility or dispersivity and enhanced stability. | 2013-01-03 |
20130004593 | CONTAINER, USE, DIALYZER OR PREPARATION UNIT AS WELL AS METHOD OF MANUFACTURING A CONCENTRATE - The present invention relates to a container comprising at least a dry concentrate, wherein the dry concentrate is designed such that it forms at least one acid liquid concentrate, or a part of an acid liquid concentrate, which is suitable for manufacturing at least on dialysis solution, on its dissolving in a liquid, preferably in water. | 2013-01-03 |
20130004594 | ORAL REHYDRATION COMPOSITION - Disclosed are oral rehydration compositions with sucrose, or alternatively fructose and glucose in a 1:1 ratio. The composition further comprises an osmolarity of below 250 mOsm/L, and sodium below 75 meq/L. Further disclosed are methods of treatment using the same. | 2013-01-03 |
20130004595 | Compositions and Methods for Treating Skin Conditions - Provided are skin treatment compositions comprising an | 2013-01-03 |
20130004596 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES CONTAINING QUAMOCLIT ANGULATA EXTRACT - The present invention relates to a pharmaceutical composition for treating diabetes and its complications, containing a | 2013-01-03 |
20130004597 | HERBAL MEDICINAL COMPOSITION AND EXTRACT THEREOF FOR INHIBITING GROWTH OF CANCER CELLS - The present invention relates to herbal medicinal compositions and extracts thereof for inhibiting growth of cancer cells. One of the examples described in the present invention comprises | 2013-01-03 |
20130004598 | Herbal Preparation for Anemia and a Manufacture Method Thereof - A herbal extract for anemia is obtained by a process including steps of drying, by providing a herbal material comprising dry mulberry and dry | 2013-01-03 |
20130004599 | FORMULATION FOR TRANSDERMAL DELIVERY TO PROMOTE SLEEP - A topically administered composition to promote sleep, comprising | 2013-01-03 |
20130004600 | Animal repellent composition - A liquid animal repellent composition having a liquid phase and an oil phase, the composition having oleoresins of capsicum, black pepper and rosemary along with surfactants and preservatives. A pH adjuster is also utilized. | 2013-01-03 |
20130004601 | APPETITE REGULATING DIETARY SUPPLEMENT - A dietary supplement for regulating the appetite of an individual is described. The dietary supplement comprises at least one mechanical satiety regulator, and at least one chemical satiety inducer, and may additionally comprise at least one thermogen, and/or at least one side effect remover. The dietary supplement induces satiety based on a combination of occupying part of the volume of the stomach, inducing sending signals to the brain in respect of satiety. Furthermore the dietary supplement may maintain or increase metabolism and reduce side effects such as the amount of produced flatulence. The dietary supplement may comprise fibre, whey, plant parts from plants e.g. of the genus | 2013-01-03 |
20130004602 | LOTION COMPOSITION AND FIBROUS STRUCTURE COMPRISING SAME - A lotion composition containing a microcrystalline wax, a fibrous structure containing such lotion composition and a method for making such fibrous structure and/or lotion composition are provided. | 2013-01-03 |
20130004603 | WASP, HORNET, AND YELLOWJACKET SPRAY REPELLANT AND NEST PESTICIDE - Methods for killing insects and a nest are disclosed. The methods may be used to disrupt a colony of nest-dwelling insects. The insects may include wasps, hornets, and yellowjackets. | 2013-01-03 |
20130004604 | DARK CHOCOLATE DELIVERY SYSTEM FOR A COMBINATION OF DIETARY SUPPLEMENTS AND PHARMACEUTICALS - An edible, chewable dark chocolate candy for the oral delivery of dietary supplements and pharmaceutical compounds. The-chocolate formed or molded solid candy contains at least one active ingredient that is blended with the chocolate candy during conching of the chocolate candy. A method for manufacturing the chewable chocolate candy is also disclosed. In the blending phase, a chocolate liquor is blended with additional ingredients to obtain the desired individual chocolate recipe for the chocolate delivery vehicle. The selected dietary supplement and/or pharmaceutical compounds are then added to the chocolate liquor, which is then conched for the desired time period. When the conching phase is completed, the conched chocolate is tempered, after which the tempered chocolate having 60% or more cacao mass may be formed into various sizes and shapes for individually-wrapped pieces, or formed into large blocks for storage and shipment. | 2013-01-03 |
20130004605 | HERBAL MEDICINAL COMPOSITION AND EXTRACT THEREOF FOR INHIBITING GROWTH OF CANCER CELLS - The present invention relates to herbal medicinal compositions and extracts thereof for inhibiting growth of cancer cells. One of the examples described in the present invention comprises Forsythiae (ructus, Menthae Herba, Gardeniae Fructus, Scutellariae Radix, Lophatheri Folium, Glycyrrhizae Radix, Rhei Rhizoma, Na | 2013-01-03 |
20130004606 | Underwater Pelletizer - An Underwater pelletizer for cutting extruded plastic into a flow of liquid. The pelletizer includes a cutter hub ( | 2013-01-03 |